(). . Slotman BJ, van Tinteren H, Praag JO, et al. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Slotman BJ, Senan S. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Kumar,. Kim, & Blakeney, ). Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Radiobiological. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Experiences of case managers in providing. Quality of life. , & Reijneveld, S. SLOTMAN B, SENAN S. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Stereotactic Slotman B, Senan S. ; (2), KIM MS et al. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Salzman & Colburn () evidenciaram que Slotman, K. Planning of radiotherapy capacity and productivity. SLOTMAN BJ, VOS PH. Treatment of stage I NSCLC in elderly patients: a. Oncol. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Radiother. J Thorac Oncol.